3,601 results on '"Valent, Peter"'
Search Results
2. Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)
3. Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
4. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study
5. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
6. Clonal medicine targeting DNA damage response eradicates leukemia
7. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
8. Megafloods in Europe can be anticipated from observations in hydrologically similar catchments
9. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
10. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
11. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
12. Mast cell activation syndrome: Current understanding and research needs
13. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
14. The testing of a multivariate probabilistic framework for reservoir safety evaluation and flood risks assessment in Slovakia: A study on the Parná and Belá Rivers
15. Effects of the application of biochar on the soil erosion of plots of sloping agricultural and with silt loam soil
16. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
17. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
18. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
19. Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis
20. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
21. Imatinib-resistant chronic myeloid leukemia (CML) : current concepts on pathogenesis and new emerging pharmacologic approaches
22. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
23. Analysis of Nitrate Concentrations Using Nonlinear Time Series Models
24. World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives
25. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies
26. Affective temperament, fatigue, and pain in cancer patients
27. The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients
28. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
29. Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis
30. Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers
31. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
32. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
33. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
34. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
35. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
36. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
37. Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment
38. HOchwasserRisikozonierung Austria 3.0 (HORA 3.0)
39. Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients
40. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
41. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
42. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
43. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
44. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
45. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
46. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
47. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
48. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
49. Impact of interest rates on forest management planning based on multi-criteria decision analysis
50. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.